This paper describes that the compound has been studied against cancers, including breast, bladder, oral, lung, leukemia, and hepatocellular carcinomas, and that casticin inhibits the invasion, migration, and proliferation of cancer cells and induces apoptosis (casticin-induced, ROS-mediated, and mitochondrial-dependent) and cell cycle arrest (G0/G1, G2/M, etc.)through different signaling pathways, namely the PI3K/Akt, NF-κB, STAT3, and FOXO3a/FoxM1 pathways. Here, NFKB1 is linked to hepatocellular carcinoma.